MX2019001850A - Formulaciones para administracion oral de principios activos. - Google Patents

Formulaciones para administracion oral de principios activos.

Info

Publication number
MX2019001850A
MX2019001850A MX2019001850A MX2019001850A MX2019001850A MX 2019001850 A MX2019001850 A MX 2019001850A MX 2019001850 A MX2019001850 A MX 2019001850A MX 2019001850 A MX2019001850 A MX 2019001850A MX 2019001850 A MX2019001850 A MX 2019001850A
Authority
MX
Mexico
Prior art keywords
oral administration
formulations
active principle
active agents
therapeutically active
Prior art date
Application number
MX2019001850A
Other languages
English (en)
Spanish (es)
Inventor
Burshtein Gregory
Rothner Ariel
M Schwartz Phillip
GALITZER Hillel
Original Assignee
Entera Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entera Bio Ltd filed Critical Entera Bio Ltd
Publication of MX2019001850A publication Critical patent/MX2019001850A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019001850A 2016-08-17 2017-08-17 Formulaciones para administracion oral de principios activos. MX2019001850A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662375989P 2016-08-17 2016-08-17
PCT/IL2017/050920 WO2018033927A1 (en) 2016-08-17 2017-08-17 Formulations for oral administration of active agents

Publications (1)

Publication Number Publication Date
MX2019001850A true MX2019001850A (es) 2019-05-15

Family

ID=61196521

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001850A MX2019001850A (es) 2016-08-17 2017-08-17 Formulaciones para administracion oral de principios activos.

Country Status (14)

Country Link
US (2) US12239691B2 (enExample)
EP (1) EP3500291A4 (enExample)
JP (4) JP7530173B2 (enExample)
KR (4) KR20230088854A (enExample)
CN (4) CN109862906A (enExample)
AU (2) AU2017311698B2 (enExample)
BR (1) BR112019003136A2 (enExample)
CA (1) CA3033259A1 (enExample)
IL (3) IL312218B2 (enExample)
MX (1) MX2019001850A (enExample)
NZ (1) NZ751668A (enExample)
SG (1) SG11201901070YA (enExample)
WO (1) WO2018033927A1 (enExample)
ZA (1) ZA201901370B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128972A1 (en) * 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
MX2019001850A (es) * 2016-08-17 2019-05-15 Entera Bio Ltd Formulaciones para administracion oral de principios activos.
US12303487B2 (en) * 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
CN115209910A (zh) * 2020-03-18 2022-10-18 四川海思科制药有限公司 口服药物组合物
AU2023226092A1 (en) * 2022-02-24 2024-10-03 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone
WO2023161936A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone
KR20240152915A (ko) * 2022-02-24 2024-10-22 엔테라 바이오 리미티드 활성제의 경구 투여를 위한 산 중화 중합체를 포함하는 제형
WO2025046589A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360793A (en) 1993-05-24 1994-11-01 Sterling Winthrop Inc. Rafting antacid formulation
US6875856B2 (en) 1993-09-24 2005-04-05 Syntro Corporation Recombinant infectious laryngotracheitis virus and uses thereof
CN1162917A (zh) 1994-10-07 1997-10-22 伯温德药品服务公司 肠内涂层组合物，用其涂覆的方法和涂覆制品
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2220301C (en) 1995-06-02 2006-02-21 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
JP3880093B2 (ja) 1995-08-08 2007-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 錠剤
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
CN1228708A (zh) 1996-09-04 1999-09-15 有限会社多特 经口给药用含肽药物组合物
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
AU3240900A (en) 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
EP1163209A4 (en) 1999-02-26 2004-12-29 Emisphere Tech Inc COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
MXPA02004092A (es) 1999-11-05 2003-02-12 Emisphere Tech Inc Compuestos y composiciones de acido fenilaminocarboxilico para administrar agentes activos.
AU1594801A (en) 1999-11-12 2001-06-06 Emisphere Technologies, Inc. Liquid heparin formulation
DE60233803D1 (de) 2001-08-17 2009-11-05 Novartis Ag 5-cnac zur oralen verabreichung von parathormonfragmenten
BR0214199A (pt) 2001-11-13 2005-01-04 Emisphere Tech Inc Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração
CA2466863A1 (en) 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
CA2469673A1 (en) * 2001-12-19 2003-06-26 Sanwa Kagaku Kenkyusho Co., Ltd. Controlled release molded product
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
AR040737A1 (es) 2002-08-01 2005-04-20 Novartis Ag Administracion oral de calcitonina
JP2007525472A (ja) * 2003-07-04 2007-09-06 ニコメド ダンマーク エイピーエス 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物
JP2005281231A (ja) 2004-03-30 2005-10-13 Bioserentack Co Ltd 小腸ターゲットタイプの経口ｄｄｓ製剤
US20060052306A1 (en) 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP2006111558A (ja) 2004-10-14 2006-04-27 Bioserentack Co Ltd 多層構造を有する錠剤状の小腸粘膜付着性経口製剤
JP2008520726A (ja) * 2004-11-19 2008-06-19 スミスクライン・ビーチャム・コーポレイション 医薬製品
US8110547B2 (en) 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
JP5175553B2 (ja) * 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
JP5123471B2 (ja) 2005-08-18 2013-01-23 帝人ファーマ株式会社 用量調整が容易な製剤
EP2722054B1 (en) 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
SI2952197T1 (sl) 2005-10-26 2017-09-29 Cydex Pharmaceuticals, Inc. Sestavki sulfoalkil eter ciklodekstrina in metode priprave le-tega
AU2006318815B2 (en) 2005-11-17 2010-08-19 Novartis Ag Pharmaceutical composition
US20070178155A1 (en) 2006-01-31 2007-08-02 Jiang David Yihai Preparation for gastric buoyant sustained drug release dosage form
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US8703821B2 (en) 2006-04-18 2014-04-22 Emisphere Technologies Inc. Dialkyl ether delivery agents
EP2061440A2 (en) * 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
US20100303901A1 (en) 2007-04-26 2010-12-02 Eyal Shimoni Oral delivery of proteins and peptides
JP2010539096A (ja) 2007-09-11 2010-12-16 オラヘルス コーポレーション 咽喉、食道及び胃の治療のための局所的に活性である成分を放出する接着トローチ
WO2009080764A2 (en) 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
IT1393244B1 (it) * 2008-07-18 2012-04-12 Universita' Degli Studi Di Milano Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale
CN102123697B (zh) 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
EP2558106A1 (en) 2010-04-16 2013-02-20 Novartis AG Methods and compositions for improving implant osseointegration
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
EP2747563A4 (en) 2011-08-26 2015-06-24 Aegis Therapeutics Llc COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
US9803731B2 (en) 2014-04-24 2017-10-31 American Axle & Manufacturing, Inc. Actuator device having cam and follower and controller configured to employ rate-based methodology to identify positioning of follower on cam at predetermined location
EP2975118B1 (en) 2014-07-16 2016-08-24 Johann Wolfgang Goethe-Universität, Frankfurt am Main Generation of a mesenchymal stromal cell bank from the pooled mononuclear cells of multiple bone marrow donors
WO2016128972A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
MX2019001850A (es) 2016-08-17 2019-05-15 Entera Bio Ltd Formulaciones para administracion oral de principios activos.
JP7419862B2 (ja) 2020-02-14 2024-01-23 株式会社リコー 潤滑剤供給装置、プロセスカートリッジ、及び、画像形成装置

Also Published As

Publication number Publication date
CN116831978A (zh) 2023-10-03
EP3500291A4 (en) 2020-03-11
SG11201901070YA (en) 2019-03-28
US20240415936A1 (en) 2024-12-19
KR102832566B1 (ko) 2025-07-09
US20190209657A1 (en) 2019-07-11
JP2025114692A (ja) 2025-08-05
US12239691B2 (en) 2025-03-04
JP2024054222A (ja) 2024-04-16
IL312218B1 (en) 2025-07-01
CA3033259A1 (en) 2018-02-22
IL264880A (en) 2019-04-30
EP3500291A1 (en) 2019-06-26
BR112019003136A2 (pt) 2019-05-21
AU2024211004A1 (en) 2024-09-05
ZA201901370B (en) 2025-07-30
CN109862906A (zh) 2019-06-07
JP2019524836A (ja) 2019-09-05
KR102832565B1 (ko) 2025-07-09
KR20240093678A (ko) 2024-06-24
KR20230088854A (ko) 2023-06-20
IL264880B1 (en) 2024-05-01
CN116831977A (zh) 2023-10-03
AU2017311698B2 (en) 2024-09-05
WO2018033927A1 (en) 2018-02-22
IL312218B2 (en) 2025-11-01
KR20240134254A (ko) 2024-09-06
KR20190039768A (ko) 2019-04-15
CN116850132A (zh) 2023-10-10
AU2017311698A1 (en) 2019-04-04
AU2024211004B2 (en) 2026-04-09
IL321113A (en) 2025-07-01
JP7736834B2 (ja) 2025-09-09
IL264880B2 (en) 2024-09-01
JP7546622B2 (ja) 2024-09-06
JP7530173B2 (ja) 2024-08-07
JP2022126766A (ja) 2022-08-30
NZ751668A (en) 2022-07-29
IL312218A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
MX2018011102A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
ZA201901370B (en) Formulations for oral administration of active agents
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
MX2022010774A (es) Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial.
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CR20160527A (es) Derivados de carboxamida
AR100369A1 (es) Composición de dosis fija de formoterol y budesonide
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol